The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CEO Overview

19 Dec 2012 07:00

RNS Number : 8592T
ViaLogy PLC
19 December 2012
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

CEO OVERVIEW

 

London, UK December 19, 2012. ViaLogy PLC (LSE/AIM: VIY) In what has been a pivotal year for ViaLogy, the board sees value in offering this CEO overview to shareholders at the close of the year. This year we won contracts with large, sophisticated global operators, giving us the opportunity to demonstrate the efficacy of QuantumRD in diverse geological formations and geographical areas, to challenge best-of-practice conventional seismic techniques with our results, and to show that our technology can command revenues at premium prices. We have steered a deliberate course away from smaller US independents to large global players with the end objective of achieving large-scale industry use of QuantumRD, and major growth in revenue and shareholder value. Much has been achieved and much remains to be done.

Our contracts are for operational decision-making projects in key client assets in the real world of hydrocarbon exploration and production, a stick-with-what-you-know, risk averse industry where the take-up of new technologies must be earned. For our current fiscal year 2013 we indicated that our objectives would be successful contract performance, building client relationships and upselling, expanding our client base, growing revenues, and moving technology development forward - and accomplishing these objectives while holding costs steady. We are well aware that market expectations are focused on revenue growth; our progress is on track to meet our FY 2013 goals.

Another key objective has been to win those contracts that would subject QuantumRD to rigorous technical scrutiny and demonstrate its global reach. As we've said, this is a process, not an event. The strategy is high risk, high payoff, and we are advancing. Blue chip clients have the depth that resides in a cadre of top geophysicists to preside over evaluations that will gain respect industry-wide. Working in difficult, complex fields where QuantumRD is, so to speak, the technology of last resort; has the aim of becoming the solution of first resort in future projects. This strategy has had considerable hurdles (for example, the extended sales cycle we've encountered in selling to large corporations), but is being successfully implemented. This is because ViaLogy's value proposition - significantly offsetting capital risk prior to drilling or field development - as well as our mounting successful performance record, is compelling.

Our continuing work for Chevron is a good gauge of our progress. We are now working on their largest long term US prospect, the Delaware Basin. This work follows a seminal project success in which QuantumRD predicted a porosity trend in a sixty square kilometer field corresponding to the highest producing wells (know previously to Chevron, but blinded to ViaLogy), something not previously achieved using best-of-breed conventional analysis or geostatistical software. With Chevron's approval this success was jointly disclosed at the September international conference of the American Association of Petroleum Geophysicists. In this case, had the ViaLogy analysis been available prior to drilling, a significant reduction in the number of drilled wells would have resulted in cost savings. The work currently underway has equally promising results as it could figure in mapping optimal horizontal drilling paths through unconventional formations.

ViaLogy's typical contract performance period is about six months once seismic data of sufficient quality is received. Following the delivery of QuantumRD analysis, consultations occur with the client who then begins an internal assessment in which ViaLogy results are compared to and used with results from other techniques. Most large companies use standard workflows to make investment and drilling decisions. Experiments are rare, which is why patience is important in gaining acceptance of QuantumRD as a routinely used tool. ViaLogy's work for the Oil and Natural Gas Corporation of India (ONGC) is an example. The contract is a signal achievement - a non-competitive, sole source win because of the perceived value of the technology; an exceptional, national level decision to export specific offshore seismic data sets; the future business opportunity to bring QuantumRD to bear in further development of India's most important field; and, finally, a direct face-off with previously used analysis techniques. The first phase of the work extends into the spring of next year.

Our contract win with another of the Supermajors to discover and map near-arctic sandstone reservoirs is a major commercial milestone, and the opportunity to demonstrate a new capability that has not been available to this client. In an industry where large E&P firms normally confine outside contractors to a straightforward product delivery role, the ViaLogy project has been integrated into the client's structure and we have a level of customer intimacy, as well as an insight into evolving customer requirements, that is unusual. Identifying clients by name obliges ViaLogy to have their approval which some are unwilling to grant. This may hamper our ability to report fully to our shareholders, but it is a restriction to be respected.

Commercial contracts with three of the world's largest E&P firms are important building blocks for ViaLogy. Another essential building block central to scaling the business is QuantumRD software development - the task of incorporating the ViaLogy's patented Quantum Resonance Interferometry algorithms into robust, user friendly signal processing code capable of extracting hydrocarbon reservoir properties from ultra weak seismic amplitudes that have been traditionally filtered away and discarded, along with the valuable information they may contain. We have produced a good in-house tool, and our software platforms are at a point where we support multiple large projects. But this work needs to be accelerated and expanded.

ViaLogy entered the seismic interpretation and reservoir characterization business less than three years ago, an ambitious company with a disruptive technology that can make a fundamental impact on the economics of hydrocarbon discovery and production. Within the limits of our resources we are actively developing our sales pipeline, both with existing and new clients. A dialogue is underway with key Chinese firms, and ViaLogy has elicited interest from Brazil, West Africa, and the Middle East. We are taking steps to assure protection of our intellectual property in other major producing countries in anticipation of entry into those markets. We have been awarded patent rights in China, allowing us to begin marketing efforts there.

Finally, we are actively exploring potential partnerships to accelerate business growth. Better seismic data acquisition methods (for example, more sensitive geophones for both onshore and offshore data gathering) are in use or under development by the industry, especially the six or seven large services firms. Despite their capability to routinely pick up higher and lower frequencies, better data doesn't translate to better analysis. But such data can be leveraged by QuantumRD to produce better results.

In summary, ViaLogy has successfully concentrated its work with the largest exploration and production firms, is the subject of multiple paid, contracted operational vetting by elite industry players, and in these projects thus far has produced analysis results that have been applauded. Precedents in the industry for the uptake of new technologies, including the use of seismic data itself some fifty years ago, show a pattern not dissimilar to ViaLogy's. The board believes that 2012 has been a year of accomplishment positioning ViaLogy for major gains.

For further information contact: 

ViaLogy PLC

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734

Nominated Advisor and Broker to ViaLogy PLC (Seymour Pierce)

Mark Percy / Catherine Leftley, Corporate Finance +44 (0) 20-7107-8000

Katie Ratner / David Banks, Corporate Broking +44 (0) 20-7107-8000

 

About ViaLogy:

ViaLogy provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. ViaLogy's QuantumRD platform assists clients in de-risking prospects over a broad range of subsurface lithologies and complex stratigraphies to generate drilling targets, position offsets and enhance recovery. ViaLogy's core technology rapidly and accurately detects weak signals buried in high noise background and clutter, and is applicable to active/passive seismic, electromagnetic and magneto telluric data. By exploiting normally disregarded noise variations induced by changes in porosity, fluid presence and permeability across the formation, and adding computer-designed noise to the data, ViaLogy is able to amplify subtle noise variations to enhance areal and depth resolution in complex lithologies that are not achievable through conventional means. For more information on ViaLogy, visit www.vialogy.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFFAEDAFESEFE
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.